Analysts covering AbbVie have been fine tuning their models, with fair value per share adjusted slightly from US$245.22 to ...
Clinical Trials Arena on MSN

SLE: Four trials to watch in 2026

As The European Lupus Society’s 15th annual soiree approaches, the Clinical Trials Arena team takes a look at four promising ...
Also: All the news and watercooler chat from Fortune.
Studies evaluating the oral JAK inhibitor in adults and adolescents with non-segmental vitiligo are submitted for approval of the expanded indication.